{"id":470663,"date":"2021-04-05T08:03:29","date_gmt":"2021-04-05T12:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470663"},"modified":"2021-04-05T08:03:29","modified_gmt":"2021-04-05T12:03:29","slug":"selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/","title":{"rendered":"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WATERTOWN, Mass., April  05, 2021  (GLOBE NEWSWIRE) &#8212; Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta\u2019s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the virtual 20<sup>th<\/sup> Annual Needham Healthcare Conference to be held April 12-15, 2021.<\/p>\n<p>Details on the presentation can be found below.<\/p>\n<p>Date: Tuesday, April 13<br \/>Fireside chat time: 3:00 p.m. ET<br \/>Webcast: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E44YuuG4goX1o-0zhAUVTcf7Y5PoLUG53ofH61ccYwb9l2PXoowe7HEWXEULC55sJ27FG1A4BvnmxOoyp5y99FeFTk_w2jTPCxqvqu35um1UWpjE6NcoM49DxuhcxfXPkbrqKyQt2F1TlivlJ0eSO1M4lOzOQLncRhYRjeRMmbbUWI9kjxQ7dCH0Gv-HkzEMh_bVKJOPQGpbIxeLHjxctQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Click Here<\/a><\/p>\n<p>An archived webcast will also be available in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lZbiGoe-aE5kgNDlQkPXWUrvZ8WJHxX35srAv5b4T-9-ZinPBFcjghKtu79yGD0rZ4XQdBo32odHWtOAOE0SvyT_tIGlkXQkkuDFdgzOKp2ojkLG_sB87SYZXG6unnOO\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Investors &amp; Media<\/a> section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1mn8-oFwCmi8VwrPjh6oFP-CnHmPnPl1IAGxe6h8YX3_exetct6PHwgf7RD1QcSCbR8dAo1DPUVRcXaYNM9XDUU7FbD5k7twXMQLBvQSsYo=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.selectabio.com<\/a>.<\/p>\n<p>\n        <strong>About\u00a0Selecta Biosciences, Inc.<\/strong><br \/>\n        <br \/>Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body\u2019s natural self-tolerance in autoimmune diseases. The company\u2019s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1mn8-oFwCmi8VwrPjh6oFKaji-otgRZcZrcll3l147N6MTt-FHwY_sBJYqww9dnNksps5fZOMjyB-zOsGgqjg0J5vmKXqKf7D13rZbQW9f0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.selectabio.com<\/a>.<\/p>\n<p>\n        <strong>For Investors:<\/strong><br \/>\n        <br \/>Bruce Mackle<br \/>LifeSci Advisors, LLC<br \/>+1-929-469-3859<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t13Hb8xO7MTIVrUDsThHqlGiAFsASHQRQoC41GqkNSIsolO0lst_JiA2rEUuztH1CULBc4tqklm0gKQ35mgY-KZMQ7Vcv-GnRa6ZkTNjh3qG5oZad1m4eOcfftr1ZEQN\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>For Media: <\/strong><br \/>\n        <br \/>Meredith Sosulski, Ph.D.<br \/>LifeSci Communications, LLC<br \/>+1-929-469-3851<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8C5JrPJEhYkJvUWwEC4SwcVzfPxNaxs8dtNlsLxTpg6SjUtfWQmN-4gyz5euRzGcCFoFSAayPpGgREfGEj7Z9HXxZFw_nexeIw6jez7tIw7h8l3iTty2GIU7MKHl59Lq\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">msosulski@lifescicomms.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f7010a1a-1e37-4f8b-9545-6e859dd4906b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) &#8212; Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta\u2019s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the virtual 20th Annual Needham Healthcare Conference to be held April 12-15, 2021. Details on the presentation can be found below. Date: Tuesday, April 13Fireside chat time: 3:00 p.m. ETWebcast: Click Here An archived webcast will also be available in the Investors &amp; Media section of the company\u2019s website at www.selectabio.com. About\u00a0Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR\u2122 platform to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-470663","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) &#8212; Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta\u2019s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the virtual 20th Annual Needham Healthcare Conference to be held April 12-15, 2021. Details on the presentation can be found below. Date: Tuesday, April 13Fireside chat time: 3:00 p.m. ETWebcast: Click Here An archived webcast will also be available in the Investors &amp; Media section of the company\u2019s website at www.selectabio.com. About\u00a0Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR\u2122 platform to &hellip; Continue reading &quot;Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-05T12:03:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference\",\"datePublished\":\"2021-04-05T12:03:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/\"},\"wordCount\":292,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/\",\"name\":\"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==\",\"datePublished\":\"2021-04-05T12:03:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference - Market Newsdesk","og_description":"WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) &#8212; Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR\u2122 platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta\u2019s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the virtual 20th Annual Needham Healthcare Conference to be held April 12-15, 2021. Details on the presentation can be found below. Date: Tuesday, April 13Fireside chat time: 3:00 p.m. ETWebcast: Click Here An archived webcast will also be available in the Investors &amp; Media section of the company\u2019s website at www.selectabio.com. About\u00a0Selecta Biosciences, Inc. Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR\u2122 platform to &hellip; Continue reading \"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-05T12:03:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference","datePublished":"2021-04-05T12:03:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/"},"wordCount":292,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/","name":"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==","datePublished":"2021-04-05T12:03:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTYxNiM0MTAwMjU5IzUwMDA3NjYxMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/selecta-biosciences-to-participate-at-the-20th-annual-needham-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=470663"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/470663\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=470663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=470663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=470663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}